FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 305 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror March 21, 2024 EMA Recommends Extension of Therapeutic Indications for Atezolizumab May 24, 2022 A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 Active Surveillance for Low-Risk Prostate Cancer Continues to Rise June 23, 2022 Load more HOT NEWS Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... ¿Tener paneles solares o vivir cerca de una granja solar puede... Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated... Strangers Buy Boy Stuffed Animals For His Birthday When His Mom...
